RxDoctor Payments Data

Jose Padilla Ortiz, MD

Cardiovascular Disease · San Juan, PRNPI 1134235187

Payments from drug & device makers

$948in general payments, 2019–2025

Across 52 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • PBG Puerto Rico LLC$499
  • Amgen$274
  • Banner Life Sciences, LLC$48
  • Boehringer Ingelheim$25
  • Pfizer$23
  • Abbott$23
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$92598%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
PBG Puerto Rico LLC27$499
Amgen14$274
Banner Life Sciences, LLC3$48
Boehringer Ingelheim1$25
Pfizer2$23
Abbott1$23
AstraZeneca1$17
Scpharmaceuticals Inc.1$15
E.r. Squibb & Sons, L.L.C.1$13
Pfizer Pharmaceuticals LLC1$11

How this compares

$948 in reported general payments places this provider in the 25th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$33,472
Medicare patients
96
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol327$379,496
EntrestoSacubitril/Valsartan283$367,172
JardianceEmpagliflozin280$355,480
XareltoRivaroxaban274$317,030
Repatha SureclickEvolocumab543$307,977
EliquisApixaban232$298,869
OzempicSemaglutide184$181,175
SynthroidLevothyroxine Sodium1,182$148,620
JanumetSitagliptin Phos/Metformin Hcl132$127,702
JanuviaSitagliptin Phosphate108$116,489
Ambrisentan35$51,966
TrulicityDulaglutide39$42,278
Propafenone Hcl640$42,011
Candesartan Cilexetil275$41,262
MounjaroTirzepatide36$38,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Synjardy Xr, Trijardy Xr$25$438,946372 claims
AstraZenecaFarxiga$17$379,496327 claims
PfizerEliquis$23$298,869232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →